Since 2000, cancer immunotherapy has been considered the most revolutionary method in the field of oncology and has changed the cancer treatment paradigm. Companies have developed a promising type of treatment that recognizes the human body’s immune system to identify and subsequently eliminate cancerous cells in patients with different types of cancer. As the understanding of cancer immunotherapy grows quickly, some of the recent trends and new developments in this area are following.
Advancements in Checkpoint Inhibitors
· August 2024 – Merck announced that PD-L1 expression thresholds for certain advanced gastric, gastroesophageal junction (GEJ) and esophageal cancer indications for immune checkpoint inhibitors, including KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, will be discussed during an upcoming meeting of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC).
· August 2022 – Bristol Myers Squibb announced that OpdualagTM (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.1 The approval is based on the Phase 2/3 RELATIVITY-047 trial, which compared Opdualag (n=355) to nivolumab alone (n=359).
Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=5089
Checkpoint inhibitors have been among the prominent immunotherapeutic agents since they allow treatment to block proteins that suppress the immune system’s attack on cancerous cells. More recent discoveries in this regard are increasing the applicability of these drugs in treatment. For example, new checkpoint inhibitors are emerging to target further proteins apart from the most common PD-1 and CTLA-4 pathways. To this end, drugs that target TIM-3, LAG-3, and other novel checkpoints are in initial clinical trials and may have better positive results on patients who do not benefit from current therapies.
Explore the comprehensive research on report here– https://univdatos.com/get-a-free-sample-form-php/?product_id=5089
Browse Related Reports:
· Asthma Disease Market
· 3D Cardiac Mapping System Market
· Bone Void Fillers Market
· Rheumatoid Arthritis Market
· Oxycodone Market
Conclusion
In conclusion, immunotherapy is at the forefront of new cancer treatments, many breakthroughs are going to be driving the future of cancer immunotherapy. From checkpoint inhibitors to CAR-T cells and from integration of Artificial Intelligence and combinations this area of cancer therapy is moving fast. With time and more developments in research and new inventions in medical fields the chances to transform the way cancer is treated and provide patients a fresh lease of life increases. According to the UnivDatos Market Insights analysis, the rising number of cancer cases globally, advancements in research and development, high efficacy of immunotherapy, increasing investment and funding, advancements in biomarker identification, and rising regulatory approvals and accelerated pathways drive the Cancer Immunotherapy market. As per their “Cancer Immunotherapy Market” report, the global market was valued at USD 120 Billion in 2023, growing at a CAGR of about 10% during the forecast period from 2024 – 2032 .
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian